Theodore Pincus to Treatment Outcome
This is a "connection" page, showing publications Theodore Pincus has written about Treatment Outcome.
Connection Strength
1.667
-
Proposed severity and response criteria for Routine Assessment of Patient Index Data (RAPID3): results for categories of disease activity and response criteria in abatacept clinical trials. J Rheumatol. 2011 Dec; 38(12):2565-71.
Score: 0.219
-
Minimal Clinically Important Improvement of Routine Assessment of Patient Index Data 3 in Rheumatoid Arthritis. J Rheumatol. 2019 01; 46(1):27-30.
Score: 0.088
-
Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions. J Rheumatol. 2016 07; 43(7):1285-91.
Score: 0.074
-
Limitations of clinical trials in chronic diseases: is the efficacy of methotrexate (MTX) underestimated in polyarticular psoriatic arthritis on the basis of limitations of clinical trials more than on limitations of MTX, as was seen in rheumatoid arthritis? Clin Exp Rheumatol. 2015 Sep-Oct; 33(5 Suppl 93):S82-93.
Score: 0.072
-
Clinical trials documenting the efficacy of low-dose glucocorticoids in rheumatoid arthritis. Neuroimmunomodulation. 2015; 22(1-2):46-50.
Score: 0.067
-
The past versus the present, 1980-2004: reduction of mean initial low-dose, long-term glucocorticoid therapy in rheumatoid arthritis from 10.3 to 3.6 mg/day, concomitant with early methotrexate, with long-term effectiveness and safety of less than 5 mg/day. Neuroimmunomodulation. 2015; 22(1-2):89-103.
Score: 0.067
-
Assessing remission in rheumatoid arthritis on the basis of patient reported outcomes--advantages of using RAPID3/MDHAQ in routine care. Bull Hosp Jt Dis (2013). 2014; 72(2):136-41.
Score: 0.063
-
Possible discontinuation of therapies in inflammatory rheumatic diseases - as with initiation of therapies, a shared decision between patient and rheumatologist. Clin Exp Rheumatol. 2013 Jul-Aug; 31(4 Suppl 78):S1-3.
Score: 0.062
-
Decline of mean initial prednisone dosage from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/day. Arthritis Care Res (Hoboken). 2013 May; 65(5):729-36.
Score: 0.061
-
Can remission in rheumatoid arthritis be assessed without laboratory tests or a formal joint count? possible remission criteria based on a self-report RAPID3 score and careful joint examination in the ESPOIR cohort. J Rheumatol. 2013 Apr; 40(4):386-93.
Score: 0.060
-
RAPID3, an index of only 3 patient self-report core data set measures, but not ESR, recognizes incomplete responses to methotrexate in usual care of patients with rheumatoid arthritis. Bull Hosp Jt Dis (2013). 2013; 71(2):117-20.
Score: 0.059
-
Update on methotrexate as the anchor drug for rheumatoid arthritis. Bull Hosp Jt Dis (2013). 2013; 71 Suppl 1:S9-19.
Score: 0.059
-
Efficacy and safety of methotrexate in combination with other non-biologic disease-modifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritis. Bull Hosp Jt Dis (2013). 2013; 71 Suppl 1:S20-8.
Score: 0.059
-
Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target. Bull Hosp Jt Dis (2013). 2013; 71 Suppl 1:S33-40.
Score: 0.059
-
Effective initial and long-term prednisone in doses of less than 5 mg/day to treat rheumatoid arthritis--documentation using a patient self-report Multidimensional Health Assessment Questionnaire (MDHAQ). Bull NYU Hosp Jt Dis. 2012; 70 Suppl 1:14-20.
Score: 0.055
-
Differences in treat-to-target in patients with rheumatoid arthritis versus hypertension and diabetes--consequences for clinical care. Bull NYU Hosp Jt Dis. 2011; 69(2):104-10.
Score: 0.052
-
Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2010 Sep; 49(9):1795-6; author reply 1796-7.
Score: 0.049
-
Quantitative clinical rheumatology: "keep it simple, stupid": MDHAQ function, pain, global, and RAPID3 quantitative scores to improve and document the quality of rheumatologic care. J Rheumatol. 2009 Jun; 36(6):1099-100.
Score: 0.046
-
Can RAPID3, an index without formal joint counts or laboratory tests, serve to guide rheumatologists in tight control of rheumatoid arthritis in usual clinical care? Bull NYU Hosp Jt Dis. 2009; 67(3):254-66.
Score: 0.045
-
Time to score quantitative rheumatoid arthritis measures: 28-Joint Count, Disease Activity Score, Health Assessment Questionnaire (HAQ), Multidimensional HAQ (MDHAQ), and Routine Assessment of Patient Index Data (RAPID) scores. J Rheumatol. 2008 Apr; 35(4):603-9.
Score: 0.042
-
Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2008; 66(3):216-23.
Score: 0.042
-
Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol. 2008 Feb; 35(2):201-5.
Score: 0.041
-
Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials. J Rheumatol. 2006 Dec; 33(12):2372-5.
Score: 0.039
-
An index of patient reported outcomes (PRO-Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol. 2006 Nov; 33(11):2146-52.
Score: 0.038
-
Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria. Arthritis Rheum. 2005 Apr; 52(4):1031-6.
Score: 0.035
-
Are long-term very low doses of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful?. Ann Intern Med. 2002 Jan 01; 136(1):76-8.
Score: 0.028
-
Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort. Arthritis Care Res (Hoboken). 2018 08; 70(8):1198-1205.
Score: 0.022
-
GUEPARD treat-to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimate. Rheumatology (Oxford). 2013 Oct; 52(10):1890-7.
Score: 0.015
-
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011 Mar; 70(3):404-13.
Score: 0.013
-
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011 Mar; 63(3):573-86.
Score: 0.013
-
Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther. 2009; 11(1):R7.
Score: 0.011
-
Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum. 2008 Sep; 58(9):2642-51.
Score: 0.011